NCT03257761 - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

September 27, 2021

Study Completion Date

December 31, 2025

Conditions

Extrahepatic Bile Duct Adenocarcinoma, Biliary TypeGallbladder Adenocarcinoma, Biliary TypeMetastatic Pancreatic AdenocarcinomaRecurrent CholangiocarcinomaRecurrent Gallbladder CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Intrahepatic CholangiocarcinomaRecurrent Pancreatic CarcinomaStage III Gallbladder Cancer AJCC V7Stage III Hepatocellular Carcinoma AJCC v7Stage III Intrahepatic Cholangiocarcinoma AJCC v7Stage III Pancreatic Cancer AJCC v6 and v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Gallbladder Cancer AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Gallbladder Cancer AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7Stage IVB Gallbladder Cancer AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7Unresectable Gallbladder CarcinomaUnresectable Pancreatic Carcinoma

Interventions

BIOLOGICAL

Durvalumab

Given IV

DRUG

Guadecitabine

Given SC

Trial Locations (3)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Van Andel Research Institute

OTHER

lead

University of Southern California

OTHER